Study	Total	Experi Mean	mental SD		C Mean	Control SD	Mean Differenc	e	MD	95%-CI		Weight (random)
g = 12-13months Miglani 2022 Dupi-52 Fixed effect model Random effects model Heterogeneity: not applicabl	150		0.0700	48 48	-2.10	0.1300		\$	0.75	[0.71; 0.79] [0.71; 0.79] [0.71; 0.79]	11.0%	
g = 6-8months Miglani 2022 Dupi-24 Miglani 2022 Dupi-52 Fixed effect model Random effects model Heterogeneity: $I^2 = 98\%$, τ^2	295 438	-1.25	0.0700 0.0600			0.0900 0.0900		↓ • • •	0.65 0.61	[0.54; 0.58] [0.63; 0.67] [0.60; 0.62] [0.52; 0.69]	49.6% 89.0%	
Fixed effect model Random effects model Heterogeneity: $I^2 = 98\%$, τ^2 Residual heterogeneity: I^2 =)61, p <		270			-0.5 0	0.5		[0.61; 0.64] [0.56; 0.74]		 100.0%

Supplementary Fig. 7. Changes in nasal congestion scores from baseline in the dupilumab and ESS groups. The mean post-treatment differences at 6 and 12 months [15]. ESS, endoscopic sinus surgery; SD, standard deviation; MD, mean difference; CI, confidence interval.